Tesamorelin GHRH-R Research: GH Axis and Lipid Metabolism Cell Model Studies
Receptor Pharmacology and Mechanism of Action
Tesamorelin acts via GHRH-R (class B GPCR) Gs protein-coupled signalling mechanisms in laboratory cell model systems. The compound demonstrates selective binding affinity for growth hormone-releasing hormone receptors, initiating adenylyl cyclase activation and subsequent cAMP elevation. This modified GHRH analog incorporates an N-terminal trans-3-hexenoic acid modification that confers resistance to dipeptidyl peptidase-IV (DPP-IV) enzymatic degradation, extending its stability profile in cell culture environments.
The receptor binding kinetics show high-affinity interactions with GHRH-R, typically expressed in anterior pituitary cell lines and hypothalamic neuronal models. Upon receptor engagement, tesamorelin triggers conformational changes that facilitate G protein coupling, specifically Gαs subunit activation. This initiates the classic cAMP/protein kinase A (PKA) signalling cascade, leading to phosphorylation of cAMP response element-binding protein (CREB) and downstream transcriptional responses.
Binding Affinity Characteristics
In vitro binding studies utilizing radio-ligand displacement assays demonstrate tesamorelin's selectivity profile across GHRH receptor subtypes. The compound exhibits nanomolar binding affinity constants, with competitive inhibition curves indicating specific receptor engagement. Saturation binding experiments in transfected cell lines reveal maximum binding capacity values consistent with high-affinity receptor interactions.
Signalling Pathway Analysis
cAMP/PKA Cascade Activation
Tesamorelin-mediated GHRH-R activation triggers robust adenylyl cyclase stimulation in cell-based assay systems. Time-course experiments measuring intracellular cAMP accumulation show peak responses within 15-30 minutes of compound application. The downstream PKA activation profile demonstrates sustained kinase activity, with phosphorylation substrate analyses confirming pathway engagement through specific target recognition.
Transcriptional Regulation Mechanisms
CREB phosphorylation studies in responsive cell lines reveal time-dependent activation patterns following tesamorelin treatment. ChIP-seq analyses identify growth hormone gene promoter regions as primary transcriptional targets, with enhanced RNA polymerase II recruitment observed at CREB response elements. Real-time PCR validation confirms elevated growth hormone mRNA expression levels in pituitary cell culture models.
Cellular Model Systems
Pituitary Cell Line Studies
Primary research employs GH3 rat pituitary adenoma cells and human pituitary cell cultures for tesamorelin pharmacology characterization. These model systems express endogenous GHRH-R and maintain physiologically relevant signalling machinery. Dose-response curves generated in these cellular contexts demonstrate EC50 values in the nanomolar range for growth hormone secretion stimulation.
Transfected Cell Expression Systems
HEK293 and CHO cell lines transfected with recombinant GHRH-R provide controlled experimental platforms for detailed receptor pharmacology studies. These systems enable precise manipulation of receptor expression levels and concurrent measurement of signalling pathway activation. Calcium mobilization assays in these transfected models confirm G protein-coupled signalling mechanisms independent of endogenous receptor expression.
Metabolic Pathway Integration
Lipid Metabolism Signalling
In vitro studies utilizing hepatocyte cell lines and adipocyte models investigate tesamorelin's indirect effects on lipid metabolism pathways. Growth hormone-responsive cell cultures demonstrate altered gene expression profiles for enzymes involved in lipolysis and lipogenesis following compound treatment. Metabolic flux analyses reveal changes in fatty acid oxidation rates and triglyceride metabolism in responsive cell populations.
Myocyte Signalling Networks
Skeletal muscle cell culture experiments examine downstream effects of growth hormone axis activation on myocyte signalling pathways. C2C12 myoblast studies show enhanced protein synthesis markers and altered expression of growth-related transcription factors following tesamorelin treatment protocols. These cellular responses correlate with activation of IGF-1 signalling networks and mTOR pathway components.
Enzyme Kinetics and Degradation Resistance
The DPP-IV resistance modification incorporated into tesamorelin's structure demonstrates superior stability profiles in enzymatic degradation assays. Incubation studies with purified DPP-IV enzyme show minimal cleavage activity compared to native GHRH peptides. This enhanced stability translates to prolonged biological activity in cell culture systems, with sustained cAMP responses observed over extended time periods.
Mass spectrometry analyses of tesamorelin degradation products identify primary metabolic pathways and confirm the protective effects of the N-terminal modification. These stability studies inform optimal experimental conditions for in vitro research applications.
Research Summary
Tesamorelin represents a valuable research tool for investigating GHRH-R pharmacology and growth hormone axis signalling in cellular model systems. Its enhanced DPP-IV resistance and selective receptor binding profile make it particularly suitable for extended cell culture studies examining growth hormone-mediated signalling cascades. The compound's well-characterized mechanism of action through Gs/cAMP/PKA pathways provides reliable experimental outcomes for metabolic research applications across diverse cell culture models.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Hexarelin
TB-500
Epithalon
Ipamorelin
Tirzepatide
CJC-1295 DAC
PT-141
Semaglutide
Selank
BPC-157
Sermorelin
Melanotan 2
IGF LR3
Tesamorelin
AICAR
IGF-DES
GHRP 2
Albuterol
Tamoxifen
Letrozole
Clomiphene
Tadalafil
Clenbuterol
Anastrozole
Finasteride
Exemestane
Sildenafil
Yohimbine
Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows
Already a customer? Sign In
Create Account
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Sarms
Stacks
Research Liquids
Albuterol 5MG/ML | 30ML with dropper
Anastrozole 1.5MG/ML | 30ML with dropper
Clomiphene 50MG/ML | 30ML with dropper
Finasteride 5MG/ML | 30ML with dropper
Letrozole 3.5 MG/ML | 30ML with dropper
LiquiCia 30MG/ML | 30ML with dropper
LiquiCia T50 50MG/ML | 30ML with dropper
LiquiClen 200MCG/ML | 30ML with dropper
Liquistane / Exemestane 25MG/ML | 30ML with dropper
LiquiTamo 20MG/ML | 30ML with dropper
LiquiVia 25MG/ML | 30 ML with dropper
T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper
Toremifene Citrate 60MG/ML | 30ML with dropper
Yohimbine HCL 10MG/ML | 30ML with dropper
Research Peptides
Aicar 50MG
BPC-157 + TB-500 Blend 2mg ea/ 4MG
BPC-157 5MG
CJC-1295 + DAC 2MG
CJC-1295 | No DAC 2MG
Epithalon 10MG
Frag Premium 176-191 5MG
GHK-CU Copper Peptide 50MG
GHRP-2 5MG
GHRP-6 5MG
Hexarelin 5MG
IGF-1 DES 1MG
IGF-1 LR3 1MG
Ipamorelin 5MG
Melanotan 2 10MG
NAD+ 500MG
PT-141 / Bremelanotide 10MG
GLP-1/GIP/GCG (RT)
Selank 5MG
GLP1 (SM)
Sermorelin 5MG
TB-500 5MG
GIP/GLP-1 (TZ)
PDE5 Inhibitors
GLP-1
Diluents
Bacteriostatic Water 10ML